Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium falciparum phosphatidylinositol 3-kinase (PfPI3K)
- Target
- PfPI3K
- Molecular classification
- Enzyme, Kinase, Phosphoinositide kinase, Class III phosphatidylinositol 3-kinase (Vps34 subfamily)
01
Overview
Plasmodium falciparum phosphatidylinositol 3-kinase (PfPI3K) is the sole class III PI3K enzyme identified in P. falciparum and is essential for the parasite's survival, mainly through its role in producing phosphatidylinositol 3-phosphate (PI3P) needed for vesicular trafficking, endocytosis of host hemoglobin, and functional integrity of the food vacuole and the apicoplast[1][3][5][7]. Genetic and chemical inhibition of PfPI3K blocks hemoglobin trafficking and catabolism and is lethal to blood-stage parasites[3][4][5]. This enzyme is a validated therapeutic target for antimalarial drug discovery and may be involved in the mechanism of artemisinin resistance through regulation of PI3P levels[5][7]. Selectivity is crucial for therapeutic inhibitor development due to possible cross-reactivity with host PI3Ks[4].
- Other names
- PI3KVPS34PFE0765wPF3D7_0515300phosphatidylinositol 3-kinase, class III
02
Mechanism of action
Competitive and irreversible inhibition of kinase activity (wortmannin, LY294002). Covalent, Fe^2+-mediated inhibition by dihydroartemisinin. Inhibition blocks endocytosis and hemoglobin trafficking, resulting in suppressed parasite growth and survival.
03
Biological functions
Endocytosis and trafficking of hemoglobin in the parasiteMembrane and vesicular transport/signalingProduces phosphatidylinositol 3-phosphate (PI3P), essential for food vacuole and apicoplast functionCritical for parasite survival and blood-stage development
04
Disease associations
Infection (essential for growth and survival of Plasmodium falciparum, malaria parasite)Artemisinin resistance (linked to PI3-kinase activity and PI3P levels)
05
Safety considerations
Selectivity: PI3K inhibitors must selectively target the parasite enzyme over human homologs to avoid toxicityResistance: Potential for genetic adaptation or altered PI3K regulation may reduce long-term drug efficacyOff-target effects: Some kinase inhibitors have promiscuous activity, posing a concern for human toxicity
06
Interacting drugs
Wortmannin (PI3K inhibitor)
3 more in the full profile.
07
Biomarkers
PI3P levels (as a marker of PI3K activity in the parasite)Possibly altered hemoglobin or amino acid profiles due to disrupted trafficking (experimental contexts)
Beyond the preview
Go deeper on Plasmodium falciparum phosphatidylinositol 3-kinase (PfPI3K).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Plasmodium falciparum phosphatidylinositol 3-kinase (PfPI3K).